Holen Sie sich die Stockscreener-App
1.86
5.10%
-0.10
Handel nachbörslich:
1.87
0.01
+0.54%
Schlusskurs vom Vortag:
$1.96
Offen:
$1.95
24-Stunden-Volumen:
903.23K
Relative Volume:
0.78
Marktkapitalisierung:
$42.19M
Einnahmen:
$151.12M
Nettoeinkommen (Verlust:
$-194.97M
KGV:
-0.1233
EPS:
-15.0871
Netto-Cashflow:
$-59.11M
1W Leistung:
+2.76%
1M Leistung:
-74.90%
6M Leistung:
-81.53%
1J Leistung:
-70.48%
1-Tages-Spanne:
$1.83
$1.96
1-Wochen-Bereich:
$1.82
$2.0153
52-Wochen-Spanne:
$1.79
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
1.86 | 41.28M | 151.12M | -194.97M | -59.11M | -15.09 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Rodman & Renshaw | Buy |
| 2026-02-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-13 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock - Yahoo Finance
Conferencia de resultados del 2T de 2026 de Karyopharm (KPTI): foco en la sNDA de selinexor y la liquidez - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc.KPTI - YCharts
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript - AOL.com
KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView
Why Is KPTI Stock Down 69% After-Hours Today? - Stocktwits
Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40 - simplywall.st
RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap - Stock Titan
Karyopharm Therapeutics (KPTI): Commodore Capital now reports 0.0% ownership - Stock Titan
KPTI|Karyopharm Therapeutics Inc|Price:2.015|Chg%:+0.025 - TradingKey
Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Karyopharm (KPTI) Ergebniskonferenz Q2 2026: Fokus auf Selinexor-sNDA und Liquidität - TradingKey
Karyopharm Therapeutics Inc (KPTI) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... - Yahoo! Finance Canada
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highl - GuruFocus
It's crunch time for Karyopharm as company faces potential default next month - Fierce Pharma
Karyopharm Therapeutics has cash to last only into next month - The Business Journals
Karyopharm Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August By Investing.com - Investing.com Australia
Karyopharm Therapeutics Q2 2026 Earnings Call Transcript - marketbeat.com
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August - Investing.com
Karyopharm Q2 2026 slides: myelofibrosis data shines amid cash crunch - Investing.com
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KPTI: Selinexor sNDA for myelofibrosis advances amid strong data, stable sales, and liquidity focus - TradingView
Earnings call transcript: Karyopharm Q2 2026 loss widens as cash pressure mounts - Investing.com
Karyopharm Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) 2026-08-13 - Seeking Alpha
Form 8K Karyopharm Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026 - marketscreener.com
Is Karyopharm Therapeutics Inc (KPTI) Undervalued at 64.1%? Q2 E - GuruFocus
Karyopharm Therapeutics Inc. Q2 2026: Revenue $33.4M, Net loss $67M, EPS $(2.32) — 10-Q Summary - TradingView
Karyopharm Therapeutics: Q2 Earnings Snapshot - Barchart.com
Karyopharm Reports $33.4 Million Q2 Revenue and $67 Million Net Loss - Quiver Quantitative
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission - Karyopharm
BRIEF-Karyopharm Therapeutics Q2 Net Income USD -67.023 Million - TradingView
Adage Capital reports 1.54M Karyopharm (KPTI) shares, a 6.78% stake - Stock Titan
Karyopharm Therapeutics Inc Stock Short Interest Rises to 33.51% - Quiver Quantitative
Goldman Sachs Group (KPTI) discloses 6.3% beneficial stake in Karyopharm - Stock Titan
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a shareEarnings Preview - TradingView
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - Karyopharm
Karyopharm’s Aug. 13 results call will include slides online - Stock Titan
Karyopharm Therapeutics (KPTI) Drops 7.6% to $1.96, Testing Key Support at $1.86Mutual Fund Flow - vinanet.vn
Myelofibrosis Combo Advances as Karyopharm Preps August sNDA - Streetwise Reports
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC) and Karyopharm Therapeutics (KPTI) - The Globe and Mail
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Weekly Recap: XPORT-EC-042 misses PFS endpoint and SENTRY sNDA reports SVR35 - TradingView
KPTI Stock Crashes As Trial Failure Triggers Legal Scrutiny - StocksToTrade
KPTI Stock Collapses As Trial Failure Triggers Downgrades And Legal Scrutiny - StocksToTrade
Low coffers, failed endometrial cancer trial: Karyopharm down 72% - bioworld.com
Jefferies Initiates Karyopharm Therapeutics(KPTI.US) With Buy Rating, Announces Target Price $11 - moomoo.com
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):